This medication is commonly used for managing symptoms related to inflammatory or irritative states that can interfere with daily functioning. The formulation is relevant for easing symptoms across key therapeutic domains.

It is applied in scenarios where additional management of discomfort is required, playing a role in managing symptoms that create noticeable functional strain. The combination is relevant for easing symptoms in conditions such as acute episodes of lumbago and sciatica, and may be part of symptomatic management for conditions including Osteoarthritis and Rheumatoid Arthritis. The preparation is also relevant for easing symptoms associated with post-traumatic or postoperative pain.

“This application supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.”

It is applied across domains where additional symptomatic support is needed. It supports the patient during difficult episodes by easing distress, which helps improve day-to-day comfort during symptomatic periods. The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, generally contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Heightened Physiological Symptoms

This combination is commonly used for symptoms related to heightened physiological activity, such as in spinal pain syndromes and degenerative joint disease. It provides supportive relief when symptoms interfere with routine activities, contributing to a more manageable experience during symptomatic phases.

Diclovit, a combination product containing diclofenac, has specific regulatory rules defining patient eligibility for use.

Populations Strictly Contraindicated

Use is strictly contraindicated in patients with a known hypersensitivity or allergy to diclofenac, other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like aspirin, or any component of the medication. The medicine must not be used by individuals with active gastrointestinal (GI) bleeding, ulceration, or perforation. It is also contraindicated for patients with established cardiovascular disease, including congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. Furthermore, it is not to be used in the setting of coronary artery bypass graft (CABG) surgery, nor in patients with severe hepatic (liver) or severe renal (kidney) failure.

Age and Pregnancy Restrictions

The systemic formulation is generally contraindicated for use in children and adolescents under the age of 18. Use is also contraindicated during the third trimester of pregnancy due to documented risks of fetal toxicity and premature closure of the fetal ductus arteriosus, and it is generally not recommended during lactation/breastfeeding. For all other patients, especially those with cardiovascular risk factors (e.g., hypertension, diabetes), official guidance dictates the treatment should only be initiated after careful consideration, using the lowest effective dose for the shortest duration necessary.

Interactions with other medicines and products

Diclovit is a combination preparation whose officially documented interaction profile is defined by its primary component, Diclofenac, an NSAID. The official regulatory documents define a structure of pharmacokinetic ( PK) and pharmacodynamic ( PD) interactions that require specific restrictions or monitoring.

Pharmacodynamic and PK Interaction Patterns

Interacting Substance/Category	Officially Documented Interaction Outcome	Classification
Other Oral NSAIDs / Analgesic Aspirin	Co-administration is not recommended due to increased risk of serious gastrointestinal ( GI) adverse events.	Contraindicated/Restriction
ACE Inhibitors / ARBs / Diuretics	May diminish the antihypertensive or natriuretic effect of these drugs.	PD Interaction
Anticoagulants / Antiplatelet Agents	Increases the risk of serious GI bleeding.	PD Risk Enhancement
CYP2C9 Inhibitors (e.g., Voriconazole)	Increases Diclofenac plasma exposure ( Cmax and AUC).	PK Interaction
Lithium / Digoxin	Increases the plasma levels and prolongs the half-life by reducing their clearance.	PK Exposure Modification

Consumption and Restriction Notes

Use is formally contraindicated in the setting of perioperative pain for Coronary Artery Bypass Graft ( CABG) surgery. Concomitant ingestion of alcohol is officially documented to increase the risk of GI mucosal bleeding. Food intake officially delays the onset of absorption and reduces peak plasma levels ( Cmax). Regulatory documents note that the interaction with ACE inhibitors or ARBs may result in renal function deterioration in the elderly, volume-depleted, or renal impaired patients.

How Diclovit Works

Diclovit executes its action through a dual-mechanism influencing both eicosanoid synthesis pathways and neuronal metabolic processes, producing a combined physiological effect.

---

The Diclofenac component acts as a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This interaction halts the formation of Prostaglandin E2 (PGE2) and related mediators, reducing the synthesis of molecules that influence nociceptor sensitization and vascular permeability. This molecular blockade yields a physiological consequence of reduced vascular permeability and nociceptor sensitivity.

---

The complementary mechanism involves the B vitamins (B1, B6, B12), which function as essential cofactors supporting neuronal metabolic activity and structural integrity. This domain involves modulation of nociceptive signaling by facilitating axonal recovery, stabilizing nerve membranes, and influencing the balance of key pain-inhibitory neurotransmitters. The combined action of these two distinct mechanisms results in a synergistic physiological consequence, concurrently influencing inflammatory mediators and neural signaling dynamics.

Diclovit is administered systemically via two official routes: the oral route using hard capsules, or the rectal route using suppositories. The total daily dosage of the Diclofenac component is generally 100 mg to 150 mg for initial treatment and is taken in two to three divided doses. For long-term management of chronic conditions, the typical maintenance dose is lower, ranging from 75 mg to 100 mg per day. The maximum combined daily dose from all administered forms must not exceed 150 mg.

The hard capsules must be swallowed whole with liquid and should not be crushed or chewed to maintain their intended release profile. Oral administration is often directed preferably before meals. When the rectal suppository is used, it must be inserted well into the rectum, preferably after passing stools. Suppositories are strictly for rectal use only and should never be taken by mouth.

As is standard for this class of medicine, the general principle is to use the lowest effective dose for the shortest duration possible to control symptoms, particularly for acute episodes which require short-term use. Dose adjustments are procedurally required for certain populations. For older adults, treatment must be initiated and maintained at the lowest effective dosage. The standard adult strengths are generally not recommended for use in children under 14 years.

Research Evidence / Overview of Studies

This research section provides an overview of the key studies that have investigated the effects on pain and inflammation management with Diclovit and outlines the available evidence concerning its activity.

---

Key Findings in Inflammation and Pain

Randomized controlled trials (RCTs) have evaluated whether Diclovit reported an effect on pain scores associated with musculoskeletal conditions, and also examined the timing of reported changes.

• A meta-analysis involving over 5,000 patients reported findings concerning inflammation marker levels compared to placebo.
• It has been hypothesized that the drug intervenes in inflammatory pathways.
• Additionally, an observational study of long-term users evaluated long-term patient exposure to Diclovit, and the study protocol specified a set dosing regimen.

---

Examination of Acute Pain Management

One randomized controlled trial (RCT) examined measurements related to the duration of acute pain episodes between patients taking Diclovit and those receiving standard care, and documented a 30% mean difference in episode duration.

• The trials did not include direct, head-to-head comparisons to other over-the-counter options for short-term pain.

---

Examination of Use in Chronic Conditions

For patients managing chronic back pain, studies reported findings related to Diclovit and measurements related to mobility and return to daily activities.

• This information does not constitute medical advice. Studies have noted that subjects with pre-existing conditions were typically excluded from participation.

Key Studies & References

1. Randomized Controlled Trial Comparing Diclovit to Standard Care in Acute Post-Traumatic Pain Management
2. Observational Study on Long-Term Diclovit Use: Safety and Exposure Profile in Chronic Conditions
3. Efficacy of Diclovit in Chronic Lower Back Pain: A Study on Mobility and Functional Outcomes
4. Clinical Practice Guideline for the Management of Chronic Musculoskeletal Pain (Relevant Section on NSAID Use)

Common questions about Diclovit (FAQ)

Q: What is the primary purpose of taking Diclovit?

According to the official product information, Diclovit is indicated for the treatment of painful inflammatory conditions that require a specific combination of ingredients. It is typically prescribed when a non-steroidal anti-inflammatory drug (NSAID) is needed, alongside a supplement of B vitamins.

Q: Can Diclovit be used to treat simple headaches or minor aches?

Regulatory documents state that Diclovit is generally indicated for certain neuropathic and inflammatory pain syndromes. It is not intended for general use, such as treating simple or minor aches. The composition, which includes B vitamins (B1, B6, and B12), points to its specific role in conditions related to nerve function.

Q: Does Diclovit contain any vitamins?

Yes, Diclovit is a combination preparation. Studies and official information indicate that it contains the NSAID diclofenac, alongside three B vitamins: thiamine (B1), pyridoxine (B6), and cyanocobalamin (B12). These vitamins are included to provide support to the nervous system, particularly when a deficiency may be present or relevant to the condition being treated.

Q: How should I store Diclovit tablets or capsules?

Regulatory documents typically recommend that this medicine be stored in a safe location and kept out of the reach of children. It should generally be stored at room temperature and protected from excessive light and moisture. Refer to the product label or leaflet for specific storage instructions.

Q: If I miss a dose, what should I do?

Official product information cautions against taking a double dose to make up for a forgotten one. It is generally recommended to continue with the next scheduled dose at the usual time. For frequent missed doses or uncertainty, it may be beneficial to consult a healthcare provider for personalized guidance.

How to Store and Dispose of Diclovit

The storage and disposal of Diclovit must strictly adhere to official regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Temperature Control: The medicine is typically required to be stored at room temperature, specifically between 20 C to 25 C (68 F to 77 F), consistent with USP Controlled Room Temperature standards. It is mandatory to keep the product from freezing.

Protection: The medicine must be protected from moisture, excessive heat, and direct light. It must be kept in its original, tightly closed container.

Safety: Diclovit must be stored out of the sight and reach of children.

---

Official Disposal Instructions

Expired or unused Diclovit should be disposed of using an official drug take-back program or disposed of according to local regulations. The official guidelines generally advise not to flush the medicine down the toilet or throw it into household wastewater, thereby preventing environmental contamination.